Richon, Victoria M.

Histone deacetylases and cancer: causes and therapies

Marks, P. A., Rifkind, R. A., Richon, V. M., Breslow, R., Miller, T., & Kelly, W. K. (2001) · Nature reviews. Cancer

Histone Deacetylase Inhibitors ResearchEpigenetics and DNA Methylation

Cited by 1,866

Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors

Finnin, M. S., Donigian, J. R., Cohen, A., Richon, V. M., Rifkind, R. A., Marks, P. A., Breslow, R., & Pavletich, N. P. (1999) · Nature

Histone Deacetylase Inhibitors ResearchEnzyme Structure and Function

Cited by 1,714

Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)

Duvic, M., Talpur, R., Ni, X., Zhang, C., Hazarika, P., Kelly, C., Chiao, J. H., Reilly, J. F., Ricker, J. L., Richon, V. M., et al. (2007) · Blood

Cutaneous lymphoproliferative disorders researchDermatology and Skin Diseases

Cited by 1,141

Histone deacetylase inhibitor selectively induces p21 WAF1 expression and gene-associated histone acetylation

Richon, V. M., Sandhoff, T. W., Rifkind, R. A., & Marks, P. A. (2000) · Proceedings of the National Academy of Sciences

Histone Deacetylase Inhibitors ResearchGenomics and Chromatin Dynamics

Cited by 1,090

A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases

Richon, V. M., Emiliani, S., Verdin, E., Webb, Y., Breslow, R., Rifkind, R. A., & Marks, P. A. (1998) · Proceedings of the National Academy of Sciences

Histone Deacetylase Inhibitors ResearchGenomics and Chromatin Dynamics

Cited by 914

A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells

Knutson, S. K., Wigle, T. J., Warholic, N. M., Sneeringer, C. J., Allain, C. J., Klaus, C. R., Sacks, J. D., Raimondi, A., Majer, C. R., Song, J., et al. (2012) · Nature Chemical Biology

Epigenetics and DNA MethylationCancer-related gene regulation

Cited by 776

Potent inhibition of DOT1L as treatment of MLL-fusion leukemia

Daigle, S. R., Olhava, E. J., Therkelsen, C. A., Basavapathruni, A., Jin, L., Boriack-Sjodin, P. A., Allain, C. J., Klaus, C. R., Raimondi, A., Scott, M. P., et al. (2013) · Blood

Acute Myeloid Leukemia ResearchAcute Lymphoblastic Leukemia research

Cited by 722

Histone deacetylase inhibitors as new cancer drugs

Marks, P. A., Richon, V. M., Breslow, R., & Rifkind, R. A. (2001) · Current Opinion in Oncology

Histone Deacetylase Inhibitors ResearchEpigenetics and DNA Methylation

Cited by 531

Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase.

Warrell, R. P., He, L.-Z., Richon, V., Calleja, E., & Pandolfi, P. P. (1998) · JNCI Journal of the National Cancer Institute

Retinoids in leukemia and cellular processesHistone Deacetylase Inhibitors Research

Cited by 502

Identification of a transcriptional repressor related to the noncatalytic domain of histone deacetylases 4 and 5

Zhou, X., Richon, V. M., Rifkind, R. A., & Marks, P. A. (2000) · Proceedings of the National Academy of Sciences

Histone Deacetylase Inhibitors ResearchGenomics and Chromatin Dynamics

Cited by 120